HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 原文
🆙#ESMO26 Rapid Oral 2: #LCSM Mets 🔥A Phase 2 Study of CS2009, a First-in-Class PD-1/VEGF/CTLA-4 Trispecific Antibody, in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) 🎙️Dr. Anwen Xiong 🔢2616RO 🎯1L Mono (PD-L1 TPS≥50%): ORR 81.3%, DCR 100% (n=16) 🎯1L SQ Combo (TPS<50%): ORR 75.0%, DCR 100% (n=8) ☑️NCT06741644 🔗 https://t.co/p4tFUd6NwV @OncoAlert @Larvol @myESMO @IASLC
热度 4 · 2 赞 · 0 回复 · 2 转发
会议摘要
NCT06741644NCT06741644按 - **标题 / Title：** A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors 对上
- **标题 / Title：** A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors读摘要原文 →来源：HHorinouchi · x.com